Dr. David Tabatadze, President and CEO of ZATA presented ZATA’s new generation oligonucleotides at the “Discovery on Target” meeting in Boston, MA on September 25-29, 2017 (http://www.discoveryontarget.com/Oligonucleotide-Therapeutics). The meeting addressed advances in genomics, gene editing, oligonucleotide synthesis, delivery and manufacturing.
